Long COVID in Congress: What Washington Isn’t Talking About

Why an Aging Congress and Repeated COVID Infections Are Reshaping American Government

This paper is part of the CYNAERA Long COVID Library, a growing collection of research advancing how Long COVID and other infection-associated chronic conditions are understood, measured, and addressed.

By Cynthia Adinig

The death of Senator Lindsey Graham has renewed attention to the health of an aging, heavily exposed Congress. Graham had a documented history of COVID-19, extensive domestic and international travel, repeated high-density public exposure, and advanced cardiovascular disease. While no formal Long COVID diagnosis was publicly disclosed, his profile raises a broader and largely unexamined question: how many members of Congress may be living with Long COVID or related infection-associated chronic conditions without public recognition?

Coming only weeks after the prolonged disappearance of former Senate Majority Leader Mitch McConnell following a serious medical emergency uncovered by investigative journalists, these events have reignited public concern regarding the health, age, and functional capacity of America's elected leaders (NBC News, 2026; Associated Press, 2026;). Yet the national conversation continues to focus almost exclusively on age while overlooking what may be the far greater governance challenge: the cumulative effects of infection-associated chronic illness within one of the oldest governing bodies in the democratic world.

Congress sits at the intersection of multiple converging risks. It is an aging institution with a median Senate age of 64 and a median House age of 57, substantially older than the general American workforce (Ballotpedia, 2025). Members routinely travel domestically and internationally, attend crowded hearings and committee meetings, and interact with thousands of constituents, diplomats, journalists, lobbyists, and foreign officials in enclosed environments where repeated respiratory exposure is unavoidable. Unlike many professions that transitioned toward remote or hybrid work after the pandemic, legislative service remains fundamentally dependent on sustained interpersonal contact. These occupational realities make repeated SARS-CoV-2 infection not an exceptional event, but an expected hazard of the profession.

The biological implications of repeated infection are now well established. Long COVID is recognized by the World Health Organization, the Centers for Disease Control and Prevention, and the National Academies of Sciences, Engineering, and Medicine (NASEM) as a chronic multisystem condition capable of affecting the neurological, cardiovascular, pulmonary, immune, autonomic, endocrine, and musculoskeletal systems, often producing symptoms that fluctuate over months or years (WHO, 2025; CDC, 2025; NASEM, 2024). Cognitive dysfunction, impaired executive function, post-exertional symptom exacerbation, dysautonomia, severe fatigue, and cardiovascular complications have all been documented among individuals who initially survived acute infection (Al-Aly et al., 2022; Davis et al., 2023). These are symptoms directly relevant to occupations requiring sustained cognitive performance, rapid decision-making, prolonged concentration, and continuous public engagement.

Despite these realities, no federal agency, congressional office, or major research institution has attempted to estimate the prevalence of Long COVID within Congress itself. Public discussion has relied almost entirely on voluntary disclosure, creating a visible count that is statistically incompatible with the institution's age profile, occupational exposures, and repeated infection opportunities. This white paper addresses that gap by providing the first population-based estimate of the likely congressional burden.

Applying published Long COVID prevalence estimates for older adults directly to the 535-member Congress produces a conservative estimate of approximately 134 to 178 members living with Long COVID. Because no official congressional prevalence estimate exists, this analysis uses direct epidemiological population modeling rather than diagnosis counts or voluntary disclosure. The estimate is intentionally conservative and should be interpreted as a minimum expected burden rather than an upper limit.

The analysis is further informed by CYNAERA's broader body of prevalence research. Previous work estimated that approximately 48.5 to 64.6 million U.S. adults are currently living with Long COVID, including 18 to 26 million Americans meeting corrected prevalence estimates for ME/CFS, with an even larger classification burden under broader infection-associated chronic condition modeling (Adinig, ME/CFS Prevalence in the Long COVID Era; Adinig, The Cultural Gendered Patriarchy Index).

Separate CYNAERA modeling of military and veteran populations estimated Long COVID prevalence approaching 42%, equivalent to approximately 225 members of Congress if applied directly to the current legislature. Because members of Congress generally possess greater financial resources and substantially greater access to healthcare, specialist evaluation, diagnostics, and treatment than the average American, this paper intentionally adopts the lower prevalence estimate. The military comparison is presented not as the primary estimate, but as evidence that the true congressional burden could plausibly be substantially higher than the conservative range reported here.

Public disclosure tells a very different story. Senator Tim Kaine remains one of the few members of Congress to publicly acknowledge having Long COVID and has stated that multiple Republican colleagues have also experienced the condition but have chosen not to disclose it publicly (Milken Institute, 2022; TIME, 2022). Former Senator Jim Inhofe likewise attributed his retirement in part to Long COVID and stated that "five or six others have [Long COVID], but I'm the only one who admits it." Representative Pete Stauber provides a third public example of the congressional disclosure and diagnostic gap. In a March 2026 letter to NIH Director Jay Bhattacharya, Stauber disclosed that he had experienced Long COVID symptoms for years before receiving a diagnosis, including vertigo, carpal tunnel syndrome, rheumatoid arthritis, and deterioration in hearing and vision. He stated that the subsequent diagnosis and treatment protocol “saved my life” and urged NIH to continue funding Long COVID research.

This observation fundamentally reframes how congressional prevalence should be interpreted. Public disclosure does not measure disease prevalence. It measures willingness to disclose illness within an institution where acknowledging disability may influence elections, committee assignments, leadership opportunities, fundraising, media scrutiny, and public perception.

This is the central argument of this white paper. Congress is confronting Long COVID under the worst possible institutional conditions: an aging governing body, repeated occupational exposure, increasing opportunities for reinfection, declining physiological reserve, strong incentives to conceal disability, and no standardized occupational health framework for identifying, accommodating, or monitoring chronic post-infectious illness. Unlike death or resignation, which activate clear constitutional succession mechanisms, hidden disability may persist for months or years while elected officials continue formally occupying office, creating uncertainty regarding functional capacity, democratic accountability, institutional resilience, and continuity of government.

These governance risks are emerging at the same time federal health policy is beginning to acknowledge the need for a different approach to invisible illness. HHS's TOPx Sprint for AI and Invisible Illness explicitly recognizes Long COVID, Lyme disease, autoimmune disease, and other infection-associated chronic conditions as national priorities requiring artificial intelligence, interoperable data systems, cross-condition innovation, patient partnership, and rapid deployment of practical solutions (NIH, 2026; HHS, 2026). If the federal government now recognizes that invisible illnesses require new institutional frameworks for healthcare, it must also confront an equally important question for governance itself.

The evidence suggests that Long COVID is affecting Congress on a scale far greater than public disclosure alone would indicate. The question is no longer whether Congress is affected. The question is whether the institution can continue to govern effectively without recognizing, measuring, and planning for that impact.

Quantifying Long COVID in Congress: A Direct Congressional Count

Despite Congress representing one of the oldest and most consistently exposed occupational populations in the United States, no federal agency, congressional office, or major research institution has publicly quantified the likely burden of Long COVID among its members. Public discussion has relied almost entirely on voluntary disclosure, producing a visible count that is statistically incompatible with the size, age, exposure history, and infection risk of the institution.

This paper addresses that gap by applying the documented Long COVID prevalence range for older adults directly to the 535 seats of Congress. The purpose is not to diagnose individual lawmakers. It is to quantify expected institutional burden using the same population-level approach routinely applied to workforces, age groups, and military populations. Published estimates indicate that approximately one in four to one in three older adults infected with SARS-CoV-2 may develop Long COVID or persistent post-acute symptoms, depending on population, case definition, infection period, vaccination status, and follow-up duration (Cohen et al., 2023; NASEM, 2024; CDC, 2025). Applying the lower and upper bounds to Congress's 535 seats:

Lower bound: 535 × 0.25 = 133.75 → 134 members

Upper bound: 535 × 0.333 = 178.16 → 178 members

Congressional Long COVID Prevalence: 134 to 178 members, or roughly one-quarter to one-third of Congress. Even at the lower bound, the likely burden exceeds the entire membership of the United States Senate. This is a direct population estimate, not a count of publicly disclosed diagnoses. It does not require every member to disclose an infection history or receive a formal diagnosis. Reliance on diagnosis alone would reproduce the same surveillance failures documented throughout Long COVID research, where limited clinical recognition, inconsistent diagnostic criteria, fluctuating symptoms, delayed diagnosis, unequal access to knowledgeable clinicians, and stigma substantially reduce the number of cases entering official records (NASEM, 2024; Ford et al., 2024).

As stated above, recent disclosures by members of Congress illustrate why diagnosis and voluntary disclosure are poor measures of prevalence. These examples demonstrate three distinct pathways through which congressional burden remains hidden: voluntary nondisclosure, delayed diagnosis, and symptoms that may persist for years before being correctly recognized.

The estimate is further supported by CYNAERA's 42% military and veteran comparison rate.

Applied directly to Congress:

535 × 0.42 = 224.7 → 225 members

This comparison is presented as contextual evidence rather than the primary estimate. Congress is substantially older than the active-duty military, carries greater baseline cardiovascular, metabolic, neurological, and mobility-related vulnerability, and operates without military-style health surveillance or readiness assessments. It is therefore difficult to identify a biologically credible reason the true congressional burden would decline to only the handful of publicly documented cases.

The lower estimate of 134 members is itself intentionally conservative. It applies the one-in-four prevalence estimate uniformly without separately accounting for repeated infections, exceptionally high occupational exposure, international travel, advanced Senate age, cumulative biological aging, preexisting chronic disease, or the increased risk associated with multiple SARS-CoV-2 infections. It also excludes congressional staff, Capitol Police, legislative support personnel, and executive branch officials who routinely work alongside members of Congress.

The contrast, stated plainly

Measure	Estimated Members
Publicly documented members with Long COVID	3
Conservative population estimate	134–178
Military comparison estimate	≈225

Even using three publicly documented cases, the conservative prevalence estimate remains approximately 45 to 59 times larger than the visible burden (134 ÷ 3 = 44.7; 178 ÷ 3 = 59.3). Put differently, currently documented cases represent only 1.7% to 2.2% of the conservative estimate (3 ÷ 178 = 1.69%; 3 ÷ 134 = 2.24%). Treating the publicly documented cases as the actual burden would require assuming that Long COVID affects only 0.56% of Congress (3 ÷ 535), an implausibly low prevalence for one of the oldest, most heavily traveled, and repeatedly exposed occupational populations in the nation.

This model builds upon CYNAERA's broader corrected national prevalence estimates of approximately 48.5 to 64.6 million U.S. adults living with Long COVID, including 18 to 26 million Americans with ME/CFS and 27.5 to 34.65 million under the broader ME/CFS classification burden. These estimates demonstrate that diagnosis-based surveillance consistently understates the true burden of infection-associated chronic conditions. The same epidemiological reasoning applied nationally suggests that voluntary disclosure alone cannot serve as a reliable measure of congressional prevalence.

The estimates presented in this paper are intentionally conservative. Although members of Congress experience unusually high occupational exposure through constant travel, public appearances, committee hearings, international delegations, and repeated SARS-CoV-2 exposure, the model intentionally adjusts downward to account for factors that may reduce overall risk, including higher socioeconomic status, exceptional access to healthcare, earlier diagnostic evaluation, greater access to specialists, and financial resources well above those available to most Americans.

Even after those conservative assumptions, the analysis estimates that 134 to 178 members of Congress may be living with Long COVID. Military and veteran comparison data suggest the true burden could plausibly approach 225 to 241 members, with approximately 230 members representing a reasonable upper planning estimate. The estimates presented throughout this paper should therefore be interpreted as a conservative floor, not the upper limit of the potential prevalence.

Whether the true prevalence is closer to 134, 178, or 230 members does not alter the central conclusion. Every plausible scenario points to an amount far greater than the small number of publicly documented cases currently shaping the national conversation. This estimate forms the foundation for the remainder of this paper. Long COVID in Congress is not an isolated issue involving a few publicly identified lawmakers. It is a probable institutional burden affecting enough members to influence attendance, endurance, cognitive performance, information processing, staff dependence, negotiation, committee work, oversight, continuity of government, and ultimately the exercise of democratic governance itself.

Why an Aging Congress Is Biologically More Vulnerable to Long COVID

The prevalence calculation above may still underestimate functional consequences, because Congress is not biologically representative of the general adult population. It is an unusually old occupational cohort experiencing repeated SARS-CoV-2 infection against a background of immunological aging, chronic inflammation, vascular deterioration, reduced mitochondrial reserve, cellular senescence, multimorbidity, and declining physiological resilience, systems that overlap substantially with the mechanisms implicated in Long COVID.

Preliminary medical examiner findings reported that Senator Lindsey Graham died following an aortic rupture associated with advanced atherosclerotic disease. While this paper is not a full analysis of Senator Graham's medical history, the event underscores the broader relevance of cardiovascular health within an aging Congress and Long COVID. Long COVID research has increasingly identified persistent cardiovascular complications, including coronary artery disease, endothelial dysfunction, vascular inflammation, subclinical atherosclerosis, cardiac arrhythmias, atherosclerotic disease, and heart failure, even following mild and non-hospitalized infections.

His documented infection, subsequent symptoms, functional changes, exposures, and cardiovascular outcome demonstrate substantial concordance with a recognized post-COVID vascular phenotype. Lack of a recorded diagnosis is not evidence that the criteria were not met. It may only mean the person was never evaluated, never consented to that label, never disclosed it, or died before the connection was formally investigated. These findings reinforce the importance of viewing cardiovascular resilience as part of the broader governance implications of infection-associated chronic conditions rather than considering age in isolation.

Following integration of documented infection history, age-adjusted baseline risk, cumulative occupational exposure, probable undocumented reinfection opportunity, physiological stress burden, cardiovascular vulnerability, and publicly documented outcome, Senator Lindsey Graham's profile produced an overall Public-Record IACC Concordance Estimate of 90%.

Recognizing that readers may wish to understand how individual public-record assessments are performed, Appendix A provides a detailed methodological demonstration using Senator Lindsey Graham as an illustrative case study. The appendix is intended to demonstrate the analytical framework only and should not be interpreted as a retrospective clinical diagnosis.

Biology of Aging and COVID

Immunosenescence. Aging progressively remodels innate and adaptive immune function: reduced naïve T-cell production, contraction of T-cell receptor diversity, impaired B-cell responses, and less efficient immune coordination (Lee et al., 2022; Nguyen et al., 2025). Thymic involution reduces the ability to mount diverse responses to novel pathogens, while lifetime exposure to viruses like CMV and EBV can leave fewer adaptable immune resources for a new pathogen such as SARS-CoV-2 (Bartleson et al., 2021). This creates a paradox relevant to Long COVID: reduced pathogen control paired with excessive or poorly resolved inflammation.

Inflammaging. Aging brings persistent low-grade systemic inflammation, elevated IL-6, TNF-alpha, and CRP, contributing to atherosclerosis, insulin resistance, neurodegeneration, and frailty even absent acute infection (Müller et al., 2024). SARS-CoV-2 does not enter an immunologically neutral body; in an older adult it may intensify an existing inflammatory trajectory rather than create an entirely new one, and the relationship can become self-reinforcing as senescent cells release inflammatory mediators that further sustain inflammaging (Schmitt et al., 2023).

Cellular senescence. Senescent cells stop dividing but remain biologically active, releasing inflammatory and tissue-remodeling signals that accumulate with age and contribute to fibrosis, vascular dysfunction, and frailty. Research has identified cellular senescence as a plausible mechanism connecting aging and severe COVID-19, suggesting a feedback loop in which aging

increases vulnerability to viral injury and viral injury accelerates biological aging (Schmitt et al., 2023). A 70-year-old and a 35-year-old member may develop identical Long COVID symptoms while carrying very different tissue-repair capacity, vascular integrity, and probability of recovery.

Endothelial and microvascular aging. Blood vessels stiffen and nitric oxide availability declines with age, impairing microvascular blood flow regulation. Long COVID research independently identifies persistent endothelial activation, altered coagulation, and impaired microcirculation as contributors to fatigue, cognitive impairment, and orthostatic symptoms (Poyatos et al., 2024; Fekete et al., 2025). An older lawmaker may enter infection with preexisting arterial stiffness or endothelial dysfunction that Long COVID then compounds, not necessarily producing an overt cardiovascular event but reducing cerebral perfusion, cognitive endurance, and stamina during long hearings and negotiations.

Mitochondrial aging. Reduced mitochondrial efficiency and quality control with age contributes to fatigue and reduced physical resilience generally. Long COVID research has independently identified abnormalities in cellular energy metabolism as a plausible contributor to post-exertional symptom exacerbation (Molnar et al., 2024). This matters for detection: an older member may complete one hearing or event but lack the metabolic reserve to repeat it without deterioration. The true impairment appears not during the performance but in the delayed recovery afterward.

Autonomic aging. Aging reduces baroreflex sensitivity and the body's ability to rapidly adapt to positional and physiological stress. Long COVID frequently involves dysautonomia, including POTS, orthostatic intolerance, and blood-pressure instability, that becomes more consequential layered onto age-related autonomic decline, especially given prolonged standing, rapid meeting transitions, air travel, and sustained cognitive pressure built into congressional life. Medications for hypertension, arrhythmia, or sleep further complicate an already crowded regulatory system, so symptoms are easily attributed to age or medication rather than recognized as post-infectious.

Brain aging and cognitive reserve. Average cognitive reserve, the ability to compensate for neurological injury, tends to decline with age, particularly with vascular disease, diabetes, or prior stroke. NIH has specifically flagged the interaction between SARS-CoV-2 and age-related neurodegeneration as a research priority (NIH, 2023). A member may compensate for mild age-related change for years through experience and staff support; Long COVID may erode that reserve through fatigue, impaired attention, or neuroinflammation, and the resulting decline can appear sudden even though it reflects lost compensation rather than a new disorder. Practiced political fluency during brief public appearances can mask reduced capacity for absorbing new information or sustaining performance over many hours.

Multimorbidity. Long COVID does not arrive alone. It layers onto existing hypertension, diabetes, arthritis, sleep apnea, or mild cognitive impairment, and each condition can obscure the other diagnostically. Physicians may attribute new symptoms to established disease, while post-COVID changes may destabilize disease that had been well controlled. This is a central reason prevalence based solely on formal diagnosis likely undercounts Congress: worsening cardiovascular, neurological, or metabolic trajectories can occur without anyone ever applying the Long COVID label.

Frailty. Frailty, reduced physiological reserve for maintaining equilibrium after stress, rises with age and chronic disease. A resilient person recovers near baseline after infection; a person with reduced reserve enters a cascade of weakness, cognitive decline, poor sleep, and loss of independence, each domain reinforcing the others. Long COVID's persistent inflammation, impaired energy metabolism, and autonomic dysfunction create exactly this type of prolonged systemic stress, meaning Long COVID in an older body should not be conceptualized as a list of isolated symptoms but as a potential destabilizer of an already complex physiological network.

Biological age versus chronological age. Two 70-year-old members may have dramatically different immune profiles, vascular health, and frailty status. Immune-aging research demonstrates substantial variation at the same chronological age, and SARS-CoV-2 infection may itself influence biological-aging pathways, meaning repeated infection could widen the gap between chronological and functional age across the institution. The point is not that every older member is incapable. It is that Congress concentrates a large number of people in age ranges where biological vulnerability, multimorbidity, and slower recovery are increasingly common, and Long COVID adds a new multisystem burden to that terrain.

Long COVID as an accelerator, not a uniform syndrome. The most plausible congressional risk is not an identical syndrome in every member. It is that SARS-CoV-2 interacts with each person's existing vulnerabilities and accelerates different pathways: cardiovascular instability in one member, cognitive dysfunction in another, dysautonomia or worsening diabetes in a third. Congress does not need 134–178 members to present identically for institutional capacity to be affected. It needs a significant number to decline in the specific domains the job requires: cognitive endurance, memory, cardiovascular stability, travel tolerance, and recovery following exertion.

Why this makes the estimate conservative, not alarmist. A younger and older workforce could share identical prevalence yet experience very different disability and recovery. Congress is likely to carry a heavier functional burden per case because affected members are more likely to already carry cardiovascular, neurological, and metabolic vulnerability, and more likely to have new symptoms misclassified as ordinary aging. The 134-178 range may therefore be numerically conservative while functional consequences are disproportionately large. A disease burden affecting a quarter to a third of a young population is serious; the same burden in a body responsible for war powers, federal spending, and judicial confirmation is a different category of risk.

Congress as a Workplace: Exposure, Governance Stakes, and the Institutional Blind Spot

Every profession carries occupational hazards, but members of Congress occupy a workplace unlike any other in the United States: their decisions shape military operations, federal spending, public health, judicial appointments, and the daily lives of more than 340 million Americans. Even modest reductions in cognitive performance, physical endurance, or executive function can produce consequences that extend far beyond the individual officeholder.

Congress combines an unusual demographic and occupational profile. The average senator is 64; the average representative is 57, substantially older than the general workforce (Ballotpedia, 2025), while the job itself is uniquely conducive to repeated infectious exposure: continuous travel between Washington and home states, international delegations, crowded hearings, classified briefings, campaign events, and thousands of visitors moving through congressional offices weekly. Unlike most sectors that adopted hybrid work after the pandemic, the legislative process remains fundamentally dependent on face-to-face contact.

Characteristic	Congress	U.S. Workforce
Median age	57–64	42
Frequent air travel	Very high	Low
Mass gatherings	Daily	Variable
International travel	High	Low
Public interaction	Thousands	Moderate
Remote work	Minimal	Common
Repeated SARS-CoV-2 risk	Very high	Moderate

Source: CYNAERA comparative assessment using congressional age data, federal labor-force demographics, and the occupational demands of legislative service.

Repeated exposure matters because repeated infection carries independent risk. Evidence increasingly shows that each SARS-CoV-2 infection carries risk of acute complications and post-infectious sequelae, and that reinfection may increase cumulative cardiovascular, neurological, and metabolic risk beyond the initial infection (Al-Aly et al., 2022; Bowe et al., 2022; WHO, 2025). CYNAERA's PCT Military framework identified a parallel pattern in a population sharing many of Congress's exposure characteristics, including continual travel, population mixing, and sustained operational demand, while remaining considerably younger and medically screened, unlike Congress.

Unlike nearly every other high-consequence workplace, Congress has no equivalent occupational health framework governing functional capacity. Corporations provide medical leave and fitness-for-duty evaluation; the military maintains readiness assessments; airline pilots and air traffic controllers must satisfy ongoing health standards. The Constitution sets a minimum age for service but no maximum, no routine functional assessment, and no standardized protocol for post-viral illness or cognitive screening. Health information often becomes public only after a visible event, such as hospitalization, prolonged absence, investigative reporting, or death, making congressional health management reactive rather than preventive.

This absence of infrastructure collides directly with what Long COVID actually looks like clinically. NASEM defines Long COVID as an infection-associated chronic condition that may be continuous, relapsing-remitting, or progressive, capable of impairing work and daily functioning for months or years, with severity ranging from mild to profound (NASEM, 2024a; WHO, 2025). The CDC recognizes that symptoms may emerge, resolve, and reappear, including difficulty concentrating, orthostatic symptoms, sleep disruption, and disabling fatigue (CDC, 2026a, 2026b). Peer-reviewed studies document persistent deficits in attention, episodic memory, processing speed, and executive function following COVID-19, including in patients never hospitalized during acute infection, alongside measurable neurological abnormalities such as blood-brain-barrier disruption and altered functional connectivity (Delgado-Alonso et al., 2025; Guillén et al., 2024; Hennemann et al., 2024; Greene et al., 2024; Barnden et al., 2026). Older adults face compounding vulnerability, with evidence of accelerated cognitive decline following severe COVID-19, particularly with preexisting hypertension (Liu et al., 2024).

These are precisely the functions legislative work depends on: sustained attention, working memory, verbal recall, and the ability to weigh competing evidence under time pressure. The governance concern does not require complete incapacity. It requires only that performance be distributed unevenly across many decision-makers. A member with slowed processing may lean more heavily on condensed staff summaries; a member with impaired working memory may struggle across multiday negotiations; a member with post-exertional symptom exacerbation may perform adequately during a televised hearing and deteriorate significantly hours later; a member with autonomic dysfunction may find prolonged standing or travel increasingly difficult. None of this needs to be dramatic or publicly visible to alter how legislative work gets done. Apparent public competence during a brief appearance should not be confused with full occupational functioning.

Reinfection deepens the concern rather than resetting it. The CDC states plainly that every SARS-CoV-2 infection carries a renewed risk of developing Long COVID, and that older adults face substantially higher risk of severe outcomes generally (CDC, 2025; 2026a). Congress combines both risk environments at once, an older population with years of accumulating exposure, so a member who recovered without apparent impairment after one infection may develop persistent symptoms after a later one, or an existing case may worsen with reinfection (CDC, 2026a; NASEM, 2024b).

There is also an indirect governance channel: congressional offices necessarily rely on chiefs of staff, legislative directors, and committee personnel to process enormous volumes of information, and that support is legitimate and indispensable. The risk is that chronic illness causes decision-making authority to migrate gradually toward unelected personnel without any transparent acknowledgment that a member's independent capacity has changed. Constituents elect a senator or representative, not the member's staff. When health status is concealed, the public loses the ability to tell the difference between appropriate assistance and quiet functional substitution. Congress has clear mechanisms for death, resignation, and formal vacancy. It has far weaker tools for the prolonged interval in which a member remains legally in office while functional capacity fluctuates or declines.

The stakes of that interval are national in scope. Congressional oversight shapes HHS, NIH, CDC, DoD, VA, SSA, and CMS; the Government Accountability Office has repeatedly emphasized Congress's central role in authorizing emergency spending and evaluating federal implementation, including the roughly $2.6 trillion appropriated during the initial COVID-19 emergency alone (GAO, 2020; 2021). GAO has separately warned that Long COVID can push affected workers out of employment and reduce labor-force participation broadly (GAO, 2022). If Long COVID diminishes functional capacity across millions of American workers, there is no biological basis for assuming members of Congress are exempt. On the national-security side, congressional responsibility for military authorization, intelligence oversight, and sanctions requires processing incomplete information and challenging executive-branch assumptions under time pressure; a hidden burden of fatigue or slowed processing across multiple lawmakers could weaken oversight without ever producing one visible moment of collapse. It is more likely to show up as slower response, weaker questioning, and greater reliance on unelected intermediaries.

The irony is structural: Congress has funded research into how Long COVID affects veterans,

workers, and the broader economy, while directing almost no institutional attention to whether the same disease affects Congress itself. If Long COVID is a workforce issue, Congress is part of the workforce. If it is a disability issue, elected officials require both reasonable accommodation and meaningful accountability. If it is a national-security issue, the functional resilience of Congress cannot remain outside examination. Long COVID functions here as a governance multiplier, not replacing the risks of age, cardiovascular disease, or political secrecy but interacting with each of them while remaining largely invisible to the public.

The Normalization Trap: When Long COVID Is Mistaken for Normal Aging

Many hallmark Long COVID symptoms closely resemble what is commonly attributed to normal aging. Fatigue becomes "working too hard." Memory lapses become "senior moments." Slower processing becomes "getting older." Difficulty standing through hearings becomes "old knees." What may in fact be chronic post-infectious disease is frequently dismissed as an inevitable consequence of age. This overlap creates a genuine diagnostic blind spot. Long COVID does not announce itself through one defining symptom; it presents as a complex multisystem condition, and in older adults already managing hypertension, diabetes, or arthritis, its symptoms are easily folded into preexisting disease rather than recognized as Long COVID (CDC, 2026; Davis et al., 2023). Public expectations compound the problem: Americans already expect lawmakers in their seventies and eighties to move more slowly or delegate more, so meaningful functional decline can be normalized rather than investigated.

The fluctuating nature of the condition worsens detection further. A member may perform adequately during a nationally televised hearing and experience profound exhaustion or cognitive slowing hours later (NASEM, 2024; WHO, 2025). Brief public appearances provide little insight into sustained occupational capacity, and reinfection means recovery cannot be assumed to return a member fully to baseline (Al-Aly et al., 2022; CDC, 2026). The governance implication is straightforward: if cognitive slowing or increasing staff dependence is routinely attributed to aging, institutional reform is never considered because the underlying cause remains invisible. This is not unique to Congress. The same misattribution has delayed recognition of Long COVID throughout healthcare, employment, and disability evaluation generally (NASEM, 2024; WHO, 2025), but Congress now risks repeating that error within its own institution. Aging cannot be prevented; Long COVID can be identified, accommodated, and in some cases treated. Mistaking one for the other delays intervention while functional decline continues unnoticed.

The Infection Accumulation Effect: Why Congressional Risk Continues to Grow

The congressional Long COVID burden should not be treated as a fixed estimate frozen at a single point in time. Members continue to encounter SARS-CoV-2, and the CDC states directly that each infection carries a renewed risk of developing Long COVID, with symptoms capable of emerging, persisting, resolving, or returning over months or years (CDC, 2026a). A member who appeared to recover fully from an earlier infection is not permanently removed from the risk pool.

Reinfection may also add new injury to damage from earlier infections. In a VA cohort of 443,588 people with one infection, 40,947 with reinfection, and more than 5.3 million uninfected controls, Bowe et al. found that reinfection carried higher risk of death, hospitalization, and post-acute sequelae across pulmonary, cardiovascular, hematological, neurological, and other domains, an adjusted hazard ratio of 2.17 for death and 3.32 for hospitalization compared with no reinfection, evident six months out and regardless of vaccination status in that cohort (Bowe et al., 2022). The study population skewed older, White, and male, a demographic overlap with the Senate in particular.

Population survey data show a similar dose-response pattern. Statistics Canada found prolonged symptoms (≥3 months) in 14.6% of adults reporting one infection, 25.4% with two infections, and 37.9% with three or more, a 1.7-fold and 2.6-fold increase respectively relative to one infection (Statistics Canada, 2023). A 2025 systematic review noted the per-infection risk of a later reinfection may sometimes be lower than the first infection's risk, but that cumulative lifetime risk can still rise because each additional infection creates another biological opportunity for illness. Lower risk per infection does not equal zero additional risk (Green et al., 2025). Vaccination reduces but does not eliminate this risk; booster vaccination showed a pooled odds ratio of 0.77 versus primary series alone, with Long COVID incidence still substantial through the Omicron era (Green et al., 2025).

Applying the infection gradient to Congress (Statistics Canada rates × 535 seats):

Known/suspected infections	Observed rate	Applied to 535 members
One	14.6%	~78 members
Two	25.4%	~136 members
Three or more	37.9%	~203 members
Publicly disclosed cases	<1%	1–2 members

The convergence across independently derived methods is hard to dismiss:

Method / scenario	Expected members
General-adult rate, one infection	78
General-adult rate, two infections	136
Older-adult congressional lower bound	134
Older-adult congressional upper bound	178
General-adult rate, three+ infections	203
Military-rate comparison (42%)	225

A simple independent-risk model illustrates the same principle mathematically. With cumulative probability = 1 − (1 − p)ⁿ and a conservative per-infection probability of 10%:

Infections	Cumulative probability	Applied to 535
1	10.0%	54
2	19.0%	102
3	27.1%	145
4	34.4%	184
5	41.0%	219

This model is illustrative rather than predictive. Infections are not independent, identical events, and immunity, age, and prior damage all modify true risk, but it demonstrates that even a modest per-infection risk, repeated across six-plus years of viral circulation, compounds into a large institutional burden. Many congressional infections were likely never documented, as testing declined and mild or asymptomatic infections are routinely missed, while members carry strong incentives not to publicize repeated illness.

Why accumulation compounds rather than resets. Several mechanisms plausibly connect repeated infection to cumulative harm: incomplete viral clearance and persistent antigen exposure sustaining immune activity (Green et al., 2025); progressive immune dysregulation that leaves a later infection encountering an already-altered immune system; cumulative endothelial and vascular injury across cardiovascular, hematological, neurological, and renal systems (Bowe et al., 2022); declining physiological reserve, where a member never fully returns to biological baseline between infections; and disease interaction, where reinfection worsens diabetes, destabilizes cardiovascular disease, or reduces compensation for age-related neurological change without ever being recorded as Long COVID at all.

These mechanisms compound with the aging biology already described: a member's third infection is not biologically equivalent to their first, since it occurs in a body that has aged further and may carry residual damage, additional chronic disease, or accumulated inflammatory and vascular abnormality from the infections before it. Congressional risk therefore rises as three processes move together: members age, infection opportunities accumulate, and recovery becomes less certain, without requiring every infection to produce permanent injury or every member to follow the same trajectory.

The consequence is that the Congressional Disclosure Gap can widen even as true burden increases. Members may attribute new symptoms after later infections to stress, age, or travel; others may recognize Long COVID but decline disclosure for political reasons; some may experience worsening of an established illness without ever identifying reinfection as the cause. The visible count can remain one or two while the functional burden expands through new cases, relapse, and progression. Congress is not facing a one-time post-pandemic burden that will shrink as an initial cohort recovers or leaves office. It is confronting an ongoing process in which new infections continue creating new cases and deepening existing impairment, with no indication that this stops simply because public attention has moved elsewhere.

The Congressional Disclosure Gap

The prevalence of Long COVID in Congress cannot be accurately estimated through disclosure alone. Acknowledging chronic illness may carry direct professional consequences for leadership positions, committee assignments, fundraising, media coverage, and electoral competitiveness, making disclosure a political decision as much as a medical one. CYNAERA defines this as the Congressional Disclosure Gap: the difference between the actual burden of chronic illness in Congress and the number of publicly acknowledged cases. As stigma around invisible illness increases, this gap widens.

Senator Kaine's account, his own diagnosis and his statement that multiple undisclosed Republican colleagues share it (TIME, 2022; Milken Institute, 2022), is direct confirmation from a sitting senator with firsthand knowledge that the publicly visible count is incomplete. This is consistent with a broader pattern in which congressional health events remain undisclosed until they become impossible to conceal: Representative Granger's absence surfaced only through investigative reporting after months in a senior living facility (Dallas Express, 2024); Senator McConnell's medical emergency generated weeks of uncertainty amid limited official communication (Associated Press, 2026); and Senator Graham's sudden death, despite an active public schedule including international travel days earlier, illustrates how quickly health status in Congress can shift from apparent normalcy to institutional crisis (NBC News, 2026). These cases differ in condition and outcome, which is precisely the point. The governance problem is not Long COVID alone; it is the absence of a transparent institutional framework for communicating functional health status while protecting individual privacy, and Long COVID enters an environment where concealment has already been normalized.

The disclosure problem is also consistent with CYNAERA's Cultural Gendered Patriarchy Index (CGPI™), designed to quantify how masculine cultural expectations and gendered diagnostic structures delay recognition and disclosure of chronic illness. Leave-one-component-out robustness testing produced correlations of −0.449 without the Patriarchal Structure Index, −0.511 without the care-seeking gap measure, −0.645 without the Hofstede masculinity component, and −0.603 without the Cultural Norms Index, indicating the relationship does not depend on any single component (Adinig, 2026). Congress is a concentrated environment for this mechanism: predominantly male, status-conscious, electorally competitive, and organized around public demonstrations of stamina and uninterrupted competence. CGPI™ offers a measurable cultural explanation for why biological prevalence may remain high while disclosure remains exceptionally low. The gap is not simply a preference for privacy but a predictable output of institutional incentives that make illness a liability.

Understanding this gap is essential to understanding the true governance stakes: public disclosure measures political transparency, not disease prevalence. Effective policy cannot be built on what is merely disclosed. It must account for what is statistically expected, biologically plausible, and institutionally concealed.

An Unexpected Opportunity: HHS Begins Rethinking Invisible Illness

Critiquing government is easy; recognizing genuine progress is harder, and evidence-based policy requires both. HHS's TOPx Sprint for AI and Invisible Illness represents one of the more significant conceptual shifts in recent federal chronic-disease policy. Rather than treating Long COVID, Lyme disease, and related IACCs as isolated clinical problems, it encourages interoperable, AI-enabled solutions connecting fragmented data, incorporating lived experience, and generating tools deployable in months rather than years (NIH, 2026; HHS, 2026). Evaluation criteria weigh scientific innovation alongside measurable public benefit, real-world implementation, and the meaningful incorporation of lived experience, a departure from biomedical innovation models that often reward publication or novelty over patient utility, and a shift toward recognizing patients, caregivers, and technologists as collaborative partners rather than primarily research subjects.

Secretary Robert F. Kennedy Jr.'s own experience with Lyme disease and his family's experience with Long COVID may plausibly help explain the emphasis, consistent with a broader pattern in which policy attention often follows leaders with direct or personal understanding of a condition.

This recognition of progress does not require overlooking the shortcomings of earlier federal response. The country lost valuable time, and many of the TOPx Sprint's principles could have been pursued years sooner. But good policy deserves recognition regardless of administration, and HHS's willingness to treat invisible illness as a national systems challenge is a genuine step forward.

The more pressing question is whether Congress will apply the same principles to itself. If the executive branch now acknowledges that Long COVID requires better data integration, transparency, and systems thinking, the legislative branch should show comparable leadership by recognizing that the same conditions may affect the institution responsible for governing the nation. Congress cannot credibly oversee the national response to invisible illness while remaining institutionally blind to invisible illness within its own membership, and because Long COVID does not distinguish between Republicans, Democrats, or Independents, this represents a genuine opportunity for bipartisan leadership rather than a political concession.

Congress Must Treat Long COVID as an Occupational Health Issue, Not a Political Liability

This paper does not argue that members living with Long COVID, cancer, MS, Parkinson's, or other chronic illness should be removed from office. That conclusion would be medically unsupported and would undermine the rights of millions of Americans living with chronic conditions. Disability does not eliminate leadership or judgment. The argument is that Congress has failed to modernize its occupational health framework despite overwhelming evidence that chronic illness increasingly shapes workforce participation and institutional resilience. Congress has repeatedly legislated disability protection and workplace accommodation for the country, the ADA's reasonable-accommodation framework chief among them (ADA, 1990), while maintaining no comparable framework for its own members. Federal agencies, hospitals, universities, and the military have all built occupational health infrastructure. Congress remains one of the few high-consequence American institutions without one.

Long COVID makes this gap increasingly consequential precisely because it rarely presents as permanent incapacity. Cognitive endurance and physical stamina fluctuate day to day, complicating the traditional binary of fully capable versus completely incapacitated (NASEM, 2024a; CDC, 2026a; WHO, 2025). Occupational health elsewhere has already solved for this: pilots undergo structured evaluation before returning to duty, and military personnel undergo periodic readiness assessment, not because illness is failure but because institutions recognize that protecting workforce health protects institutional performance. The current congressional culture instead treats disclosure as evidence of weakness, encouraging concealment over early intervention, which does not produce institutional strength but reduced transparency and increased governance risk.

Treating Long COVID as an occupational health issue rather than a political liability reframes the objective entirely: not determining which members are "fit" to serve, but identifying barriers to performance, reducing stigma around disclosure, and ensuring elected officials remain capable of independently exercising the responsibilities entrusted to them. This is a shift from crisis management to resilience planning, recognizing chronic illness as an expected feature of an aging workforce during the largest post-infectious chronic disease event in modern history, rather than an emergency to be managed only after it becomes a public controversy.

Modernizing Congress: A Framework for Institutional Resilience

The goal of reform is not exclusion of members living with chronic illness, nor a new vector for weaponizing health information. It is resilience, built through the following:

A confidential Congressional Occupational Health Program, modeled on programs used across federal agencies and the military, focused on prevention and functional support rather than punitive evaluation, with medical privacy protected alongside legitimate accountability needs (CDC, 2026; NASEM, 2024a).

Standardized post-infectious health assessments following significant infectious illness, evaluating functional recovery, including cognitive endurance, autonomic symptoms, post-exertional recovery, and cardiovascular complications, rather than relying solely on resolution of acute symptoms (WHO, 2025; CDC, 2026).

Normalized reasonable workplace accommodations: flexible scheduling around prolonged hearings, remote participation options where constitutionally appropriate, structured recovery periods after major travel, improved indoor air quality, and access to rehabilitation services, treated as investments in institutional effectiveness, consistent with accommodations already standard across the American workforce (ADA, 1990; Job Accommodation Network, 2025).

Voluntary confidential cognitive and functional screening, particularly following serious illness or repeated infection, administered independently with validated clinical tools and protected from political misuse, aimed at identifying treatable impairment and preserving service, not determining political fitness.

Clearer transparency standards for prolonged absences, distinguishing protected personal medical information from institutional continuity, with disclosure focused on functional status and expected duration rather than confidential medical detail, addressing the pattern of delayed communication seen in recent hospitalizations and absences (Associated Press, 2026; NBC News, 2026).

Formal recognition of infection-associated chronic conditions as a workforce and governance issue. Long COVID, ME/CFS, dysautonomia, chronic Lyme/PTLDS, and MCAS share overlapping challenges of delayed diagnosis, fragmented care, and inadequate occupational recognition, and would benefit from a unified framework rather than disease-by-disease treatment (NASEM, 2024a; IOM, 2015).

Adoption of the same systems-thinking approach now emerging at HHS, including interoperable data, AI, patient partnership, and cross-condition collaboration, applied inward to Congress's own institutional health, recognizing that legislative resilience depends on the sustained functional capacity of those entrusted to govern, not only on constitutional procedure.

None of this requires a constitutional amendment, mandatory retirement age, or compulsory disclosure of private medical records. It requires recognizing that the health of Congress is itself a matter of national infrastructure, deserving the same strategic attention the country already gives its cybersecurity, military readiness, and public health surveillance.

Conclusion: The Health of Congress Is the Health of American Democracy

The United States Congress now sits at the convergence of several reinforcing realities: one of the oldest governing bodies in the democratic world, one of the nation's highest-exposure occupations, and one of the few institutions whose collective health directly influences every aspect of American governance. An aging population possesses less physiological reserve. Repeated SARS-CoV-2 infections increase the opportunity for persistent multisystem disease. Political culture discourages disclosure. Congress has no comprehensive occupational health framework for chronic post-infectious illness. None of these conditions exists independently. Together, they create an institutional vulnerability that extends far beyond the health of any individual lawmaker.

This paper sought to answer a question that, remarkably, no federal agency, congressional office, or research institution has previously attempted to quantify: How many members of Congress may be living with Long COVID? Using published prevalence estimates for older adults, this analysis estimates that approximately 134 to 178 current members of Congress may be living with Long COVID, while military and veteran comparison data suggest the true burden could plausibly approach 225 to 241 members. Whether the actual number ultimately proves closer to the conservative estimate or the higher comparison is less important than the broader conclusion. Every evidence-based scenario points to an institutional burden far greater than the handful of publicly disclosed cases currently shaping the national conversation.

This paper does not argue that older Americans cannot serve effectively or that members living with chronic illness should be excluded from public office. Such conclusions would ignore both the scientific evidence and the lived experience of millions of Americans who continue making extraordinary contributions while managing chronic disease. Rather, it argues that Congress should be held to the same evidence-based occupational health principles it expects from every other critical American institution. Hospitals monitor physician performance. The military evaluates operational readiness. Commercial aviation requires ongoing medical certification. Yet Congress, despite carrying constitutional responsibilities unlike any other institution in the nation, continues to rely primarily on voluntary disclosure, political calculation, and investigative journalism to reveal health conditions that may influence institutional performance.

The broader implication extends well beyond Long COVID. Hidden disability, underdiagnosis, delayed recognition, and fragmented surveillance are recurring challenges across infection-associated chronic conditions. Whether considering Long COVID, ME/CFS, dysautonomia, post-treatment Lyme disease syndrome, or related conditions, institutions cannot effectively manage prevalence they fail to measure. The same correction principles that informed CYNAERA's national prevalence work also apply here: invisible illness should not be mistaken for invisible impact.

Federal health policy is already beginning to move in this direction. HHS's TOPx Sprint for AI and Invisible Illness recognizes that Long COVID, Lyme disease, autoimmune disease, and other infection-associated chronic conditions require new approaches built on artificial intelligence, interoperable data systems, cross-condition innovation, and lived experience (NIH, 2026; HHS, 2026). If the federal government now acknowledges that invisible illnesses require modern infrastructure for healthcare, Congress must ask whether it is prepared to apply those same principles to the institution responsible for writing the nation's laws.

The greatest threats to democratic continuity rarely emerge from a single catastrophic event. Institutions more often weaken gradually as unrecognized vulnerabilities accumulate over time. Long COVID does not require every member of Congress to become disabled. It requires only enough hidden impairment, distributed across enough decision-makers, to subtly influence attendance, endurance, information processing, negotiation, oversight, committee work, and legislative continuity. This paper does not diagnose any member of congress who has chosen not to disclose their Long COVID. However, the health of Congress is therefore not merely a private matter affecting elected officials. It is a question of democratic resilience, continuity of government, economic stability, national security, and public trust.

Long COVID did not create every vulnerability within our aging Congress. It exposed many that already existed while introducing a new biological challenge that cannot be understood through age alone. Measuring that impact is not an act of political criticism. It is an act of institutional preparedness. Just as the United States invests in resilient infrastructure, cybersecurity, military readiness, and emergency planning, it must also begin investing in the resilience of the people responsible for governing the nation. The first step in addressing any invisible problem is making it visible. This paper represents an effort to do exactly that.

Appendix

Demonstration of Public-Record IACC Concordance Assessment: Senator Lindsey Graham

Appendix A. Demonstration of Public-Record IACC Concordance Assessment_ Senator Lindsey Gr

Download DEMONSTRATION OF PUBLIC-RECORD IACC CONCORDANCE ASSESSMENT_ SENATOR LINDSEY GR • 81KB

Frequently Asked Questions

How many members of Congress may have Long COVID?

Based on corrected prevalence modeling, age demographics, and published Long COVID prevalence estimates among older adults, this paper estimates that approximately 134 to 178 current members of Congress may be living with Long COVID. The estimate is based on population-level epidemiological modeling and should not be interpreted as identifying specific individuals.

Why does Congress face a higher Long COVID risk than many workplaces?

Congress combines several known risk factors, including an older average age, frequent domestic and international travel, repeated exposure to large crowds, continuous public interaction, and repeated SARS-CoV-2 exposure over multiple years. These factors increase both infection risk and the cumulative biological effects associated with repeated infections.

Does this paper claim that specific members of Congress have Long COVID?

No. The paper estimates the likely institutional impact using established epidemiological methods. It does not diagnose or identify individual lawmakers.

Why don't more members of Congress publicly disclose Long COVID?

Long COVID remains an invisible illness that can include cognitive dysfunction, fatigue, dysautonomia, and other symptoms that may carry political stigma. Senator Tim Kaine has publicly stated that he knows multiple Republican members of Congress with Long COVID who have chosen not to disclose their condition.

Why does age matter with COVID?

Older adults are generally more susceptible to immune dysregulation, chronic inflammation, cardiovascular disease, and slower recovery following infection. These biological changes may increase both the likelihood and severity of Long COVID.

Can repeated COVID infections increase Long COVID risk?

Scientific evidence has shown that repeated SARS-CoV-2 infections increases the risk of developing Long COVID and may worsen existing symptoms or contribute to additional long-term complications.

Why is Long COVID a governance issue?

Congress depends on sustained cognitive performance, complex decision-making, negotiation, and prolonged legislative work. If a substantial number of lawmakers experience persistent post-viral symptoms, the effects extend beyond individual health and become an institutional governance challenge.

Does this paper suggest lawmakers should leave office?

No. The paper argues the opposite. Many individuals with Long COVID and other chronic illnesses continue to work successfully when appropriate accommodations, flexible scheduling, and workplace support are available. The goal is improved governance through recognition, transparency, and evidence-based accommodations.

What are Infection-Associated Chronic Conditions (IACCs)?

IACCs are chronic illnesses that develop following infections. They include Long COVID, ME/CFS, POTS, dysautonomia, post-treatment Lyme disease syndrome, and several related conditions that share overlapping biological mechanisms.

What is the US-CCUC™ framework?

The U.S. Chronic Condition Undercount Correction (US-CCUC™) is a CYNAERA modeling framework designed to estimate the hidden burden of chronic illnesses by accounting for underdiagnosis, delayed diagnosis, surveillance limitations, and misclassification.

Why did CYNAERA publish this paper now?

Recent national attention surrounding the health of aging members of Congress has renewed public discussion about institutional resilience and leadership continuity. This paper contributes evidence-based prevalence modeling to that conversation and explores why Long COVID deserves consideration as both a public health and governance issue.

How to Cite

Adinig, C. (2026). Long COVID in Congress: What Washington Isn't Talking About. Why an Aging Congress and Repeated COVID Infections Are Reshaping American Government. CYNAERA. https://www.cynaera.com/long-covid-congress

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Primary Chronic Trigger (PCT)™ 

• The Body First Trial Protocol™

• Adaptive Reserve Collapse™

• Long COVID Prevalence in U.S. Military

• Corrected National Prevalence Estimates for (IACCs)

• Preliminary Findings from The Eve Research Project

• ​Composite Diagnostic Fingerprint for Long COVID

• COVID-19 and Ebola: Pandemic Preparedness

• VitalGuard™ Environmental Flare Risk Engine

• The Hidden Public Health Cost of AI Data Centers

• US-CCUC Influenza™: Post-Influenza Chronic Illness

• Personalized CRISPR Remission™ for Long COVID

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Adams, J., et al. (2021). Long COVID and implications for military medicine. Military Medicine.

2. Adinig, C. (2026). US-CCUC: Correcting Surveillance-Based Prevalence Undercounting Across Infection-Associated Chronic Conditions. SSRN.

3. Air Force Times. (2026). Flu outbreak sickens more than 200 trainees at Lackland Air Force Base. Air Force Times.

4. Al-Aly, Z., Bowe, B. and Xie, Y. (2022). Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 28, 1461-1467.

5. Al-Aly, Z., Bowe, B., Xie, Y., et al. (2024). Long-term health outcomes following COVID-19 compared with seasonal influenza: A cohort study. The Lancet Infectious Diseases.

6. Al-Aly, Z., Xie, Y. and Bowe, B. (2022). High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 594, 259-264.

7. Allman, M.W.R., Marquez, A.R., Kotas, K.S. and Scatliffe-Carrion, K. (2026). Reportable Medical Events. Medical Surveillance Monthly Report. Defense Health Agency.

8. Armed Forces Health Surveillance Division. (2022). Armed Forces Reportable Medical Events Guidelines and Case Definitions. Defense Health Agency.

9. Armed Forces Health Surveillance Division. (2025). Medical Surveillance Monthly Report. Defense Health Agency.

10. Bova, A., et al. (2025). Strategies for Forecasting Long COVID in the Active Component Military Population. Defense Health Agency.

11. Brookings Institution. (2022). Long COVID and the American Workforce.

12. Centers for Disease Control and Prevention. (2024). About Chronic Symptoms Following Infections. U.S. Department of Health and Human Services.

13. Centers for Disease Control and Prevention. (2024). Clinical Overview of Long COVID.

14. Centers for Disease Control and Prevention. (2024). Long COVID.

15. Choutka, J., Jansari, V., Hornig, M. and Iwasaki, A. (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28(5), 911-923.

16. Chretien, J.P., Gaydos, J.C., Malone, J.L., et al. (2007). Global infectious disease surveillance in the U.S. military. Military Medicine.

17. Cintron, M., et al. (2026). Prevalence and symptoms of post-COVID-19 syndrome in active-duty military personnel. Military Medicine.

18. Cutler, D.M. (2022). The Economic Cost of Long COVID. Harvard University.

19. Davis, H.E., Assaf, G.S., McCorkell, L., et al. (2021). Characterizing Long COVID in an international cohort: Seven months of symptoms and their impact. EClinicalMedicine, 38.

20. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology.

21. Defense Health Agency. (2025). Strategies for Forecasting Long COVID in the Active Component Military Population.

22. Department of Defense. (2026). Department of Defense reinstates influenza vaccination requirements following Joint Base San Antonio-Lackland outbreak. U.S. Department of Defense.

23. Department of Veterans Affairs. (2025). Veterans Health Administration Annual Report.

24. Elfessi, Z., Rubinstein, I., Gordon, H., Young, L., Beshalske, A., Gardner, J., et al. (2025). Long COVID prevalence in elderly, high-risk U.S. military veterans residing in inner-city Chicago prescribed nirmatrelvir/ritonavir. CHEST, 168(Suppl.).

25. Galea, S. and Keyes, K.M. (2019). Understanding population health through epidemiologic surveillance. Annual Review of Public Health.

26. Government Accountability Office. (2024). VA Health Care: Opportunities to Improve Access and Workforce Planning.

27. Gray, G.C., Callahan, J.D., Hawksworth, A.W., et al. (1999). Respiratory diseases among military personnel. Military Medicine.

28. Holick, M.F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357, 266-281.

29. Hood, L. and Flores, M. (2012). A personal view on systems medicine and the emergence of proactive P4 medicine. New Biotechnology, 29(6), 613-624.

30. Institute of Medicine. (2008). Gulf War and Health: Volume 6. National Academies Press.

31. Jones, B.H. and Hauschild, V.D. (2015). Physical training, injury prevention and military readiness. Military Medicine.

32. Komaroff, A.L. and Lipkin, W.I. (2023). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of Long COVID. Trends in Molecular Medicine.

33. Last, J.M. (Ed.). (2014). A Dictionary of Epidemiology (6th ed.). Oxford University Press.

34. Loscalzo, J. and Barabási, A.L. (2011). Systems biology and the future of medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine.

35. National Academies of Sciences, Engineering, and Medicine. (2019). Strengthening the Military Health System.

36. National Academies of Sciences, Engineering, and Medicine. (2024). Long-Term Health Effects of COVID-19.

37. National Bureau of Economic Research. (2023). Long COVID and Labor Market Outcomes.

38. National Research Council. (2011). Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. National Academies Press.

39. Office of Management and Budget. (2025). Analytical Perspectives: Budget of the United States Government.

40. Peluso, M.J., Deeks, S.G., et al. (2023). Long COVID: Pathogenesis, clinical manifestations and treatment considerations. Nature Reviews Immunology.

41. Phetsouphanh, C., Darley, D.R., Wilson, D.B., et al. (2022). Immunological dysfunction persists for eight months following SARS-CoV-2 infection irrespective of initial disease severity. Nature Immunology, 23, 210-216.

42. Pilz, S., März, W., Cashman, K.D., et al. (2019). Rationale and plan for vitamin D food fortification. Frontiers in Endocrinology, 10.

43. Pludowski, P., Holick, M.F., Pilz, S., Wagner, C.L., Hollis, B.W., Grant, W.B., Shoenfeld, Y., Lerchbaum, E., Llewellyn, D.J., Kienreich, K. and Soni, M. (2013). Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality: A review of recent evidence. Autoimmunity Reviews, 12(10), 976-989.

44. Putrino, D., et al. (2023). Clinical care, rehabilitation and future directions for Long COVID.

45. RECOVER Initiative. (2024). Researching COVID to Enhance Recovery (RECOVER). National Institutes of Health.

46. Rothman, K.J., Greenland, S. and Lash, T.L. (2021). Modern Epidemiology (4th ed.). Wolters Kluwer.

47. Rubertone, M.V. and Brundage, J.F. (2002). The Defense Medical Surveillance System and the Department of Defense Serum Repository. American Journal of Public Health, 92(12), 1900-1904.

48. Schawaller, M., Wiemer, D., Hagen, R.M. and Frickmann, H. (2021). Infectious diseases in German military personnel after predominantly tropical deployments: A retrospective assessment over 13 years. BMJ Military Health, 167, 213-219.

49. Smith, B., Wong, C.A., Boyko, E.J., et al. (2008). The Millennium Cohort Study: Twenty-first century prospects for military and veteran health research. Military Medicine.

50. Stephens, K.A., et al. (2024). Symptom-defined post-acute sequelae of SARS-CoV-2 infection among U.S. veterans. Military Medicine.

51. Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.

52. U.S. Bureau of Labor Statistics. (2026). Employment Situation of Veterans Summary.

53. U.S. Department of Veterans Affairs. (2025). Office of Research and Development Annual Report.

54. Wander, P.L., et al. (2023). Geographic variation in ICD-10 coding of Long COVID among U.S. veterans. JAMA Network Open.

55. Washington University School of Medicine in St. Louis. (2024). Long flu has emerged as a consequence similar to Long COVID-19. Washington University School of Medicine.

56. World Health Organization. (2021). A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus.

57. Xie, Y., Xu, E., Bowe, B. and Al-Aly, Z. (2022). Long-term cardiovascular outcomes of COVID-19. Nature Medicine.